Arava Tablet, Film Coated
Product Images NDC 0088-2160

9 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Arava (NDC 0088-2160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (320f63f2 Fac3 4aee Aff8 85724e00ef52 01)

Chemical Structure (320f63f2 Fac3 4aee Aff8 85724e00ef52 01)
Chemical structure of leflunomide, the active ingredient in Arava. The diagram displays the molecular arrangement including a trifluoromethyl-substituted phenyl ring and an isoxazole ring with associated functional groups.*
FDA Label Image

Chemical Structure (320f63f2 Fac3 4aee Aff8 85724e00ef52 02)

Chemical Structure (320f63f2 Fac3 4aee Aff8 85724e00ef52 02)
Chemical structure of teriflunomide (A77 1726), related to the active ingredient leflunomide. The diagram shows the molecular arrangement with a trifluoromethyl-substituted phenyl ring, an amide group, and an enol cyanide structure.*
FDA Label Image

Figure 1 (320f63f2 Fac3 4aee Aff8 85724e00ef52 03)

Figure 1 (320f63f2 Fac3 4aee Aff8 85724e00ef52 03)
Bar chart titled '% ACR 20 Responder at Endpoint' showing percentage responses for trials with Leflunomide, Methotrexate, Placebo, and Sulfasalazine. The chart compares response percentages in three trials with various durations: Trial 1 (12 months), Trial 2 (6 months), Trial 3 (12 months). Leflunomide is present in all trials, with other treatments Methotrexate, Placebo, and Sulfasalazine included as comparators.*
FDA Label Image

Figure 2 (320f63f2 Fac3 4aee Aff8 85724e00ef52 04)

Figure 2 (320f63f2 Fac3 4aee Aff8 85724e00ef52 04)
A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over 12 months. The x-axis represents time in months from 0 to 12, and the y-axis represents percentage responders from -10% to 70%. Three groups are depicted: PL (placebo) with a circle marker, MTX (methotrexate) with a square marker, and LEF (leflunomide) with a triangle marker. LEF shows the highest percent responders throughout the trial period. The graph includes a note stating 'Last Observation Carried Forward.'*
FDA Label Image

Figure 3 (320f63f2 Fac3 4aee Aff8 85724e00ef52 05)

Figure 3 (320f63f2 Fac3 4aee Aff8 85724e00ef52 05)
A bar chart titled 'Change in Sharp Score' presenting data across three clinical trials (12 months, 6 months, and 12 months). The chart compares progression in Sharp score among treatments labeled as Leflunomide (L), Methotrexate (M), Sulfasalazine (S), and Placebo (P), showing bars indicating numeric progression values for each group over time.*
FDA Label Image

Figure 4 (320f63f2 Fac3 4aee Aff8 85724e00ef52 06)

Figure 4 (320f63f2 Fac3 4aee Aff8 85724e00ef52 06)
A bar chart titled "Change in Functional Ability Measure*" comparing the improvement in functional ability over three trials at 6 and 12 months. The vertical axis measures improvement from 0 to -0.6, with bars representing treatments Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S). Leflunomide consistently shows greater improvement, followed by Methotrexate and Sulfasalazine, with Placebo showing least improvement. The measurement is based on the HAQ Disability Index.*
FDA Label Image

Principal Display Panel (10 mg Carton)

Principal Display Panel (10 mg Carton)
Packaging label for Arava Tablets 10 mg, film-coated oral tablets containing leflunomide. The label indicates an oversized container for ease of patient use, with a quantity of 30 tablets. The labeler is sanofi-aventis U.S. LLC, Bridgewater, NJ, and the product is made in France. The label includes warnings, storage instructions, and NDC 0088-2160-30.*
FDA Label Image

Principal Display Panel (20 mg Carton)

Principal Display Panel (20 mg Carton)
Packaging label for Arava Tablets 20 mg, containing leflunomide as the active ingredient. The film-coated tablets are labeled for prescription use only and come in a container of 30 tablets. The label provides storage instructions, warnings to keep out of reach of children, and highlights the product is manufactured by sanofi-aventis U.S. LLC, with an origin in France. The container is noted to be oversized for ease of patient use.*
FDA Label Image

Principal Display Panel (100 mg Carton)

Principal Display Panel (100 mg Carton)
Packaging label for Arava Tablets leflunomide 100 mg Initiation-Dose Kit by sanofi-aventis U.S. LLC. The label includes dosing instructions for starting therapy over the first several days, a warning about the prescription status, and a photo of 20 mg and 10 mg tablets for reference. It notes the kit contains three 100-mg tablets and is marked as a physician sample, not for sale.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.